Teva Pharmaceutical Industries LimitedTEVA
NeurologyPsychiatry80 cited findings · profile updated 2026-08-26
38.10 USDnot live — refreshed daily
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited (TEVA) focuses on neurology and psychiatry. In neurology, their fremanezumab migraine clinical development program investigated fremanezumab for the treatment of episodic and chronic migraine in adults. Across all fremanezumab-treated patients (Cohort 4), 75% experienced at least 1 adverse event, with 54% experiencing at least 1 treatment-related adverse event. Injection site induration was observed in 27% of all fremanezumab-treated patients (Cohort 4), and injection site pain in 29% of all fremanezumab-treated patients (Cohort 4). In psychiatry, Teva is developing Uzedy for the treatment of schizophrenia in adults. The pivotal efficacy study, TV46000-CNS-30072, which included 543 subjects, met its primary endpoint for time to impending relapse with a statistically significant difference. Common adverse reactions for Uzedy include weight gain, dyslipidemia, hyperglycemia, increased prolactin, sedation/somnolence, and extrapyramidal symptoms. Injection site reactions were reported in 21% of patients receiving TV-46000, with 2% discontinuing due to these reactions.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Patients with at least 1 adverse event (fremanezumab 675 mg quarterly) | 69 % | Teva — Ajovy EMA EPAR public assessment report (EMEA/H/C/004833, 2019), p.80 |
| Patients with at least 1 adverse event (fremanezumab 225 mg monthly) | 61 % | Teva — Ajovy EMA EPAR public assessment report (EMEA/H/C/004833, 2019), p.80 |
| Patients with at least 1 adverse event (placebo) | 59 % | Teva — Ajovy EMA EPAR public assessment report (EMEA/H/C/004833, 2019), p.80 |
| Primary endpoint met for time to impending relapse (Study 30072) | statistically significant difference | Teva Pharmaceutical Industries Limited — Uzedy FDA Review (NDA213586), p.12 |
| Injection site reactions (TV-46000) | 21 % | Teva Pharmaceutical Industries Limited — Uzedy FDA Review (NDA213586), p.18 |
| Discontinuation due to injection site reactions (TV-46000) | 2 % | Teva Pharmaceutical Industries Limited — Uzedy FDA Review (NDA213586), p.18 |
Key projects
- fremanezumab (migraine) — EU
The indication applied for was the treatment of episodic and chronic migraine in adults.
- Uzedy (schizophrenia) — US
The applicant proposed indication(s)/population(s) is the treatment of schizophrenia.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Neurology research library →